CD8+ T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease
The exact mechanism of glatiramer acetate (GA, Copaxone®), an FDA-approved immunomodulatory therapy for multiple sclerosis (MS), remains unclear after decades of research. Previously, we have shown that GA therapy of MS induces CD8+ T cell responses that can potentially suppress pathogenic CD4+ T ce...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Public Library of Science
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689655/ |